BR9611007A - Antagonistas do receptor at1 para prevenir e tratar a deficiência renal pós-isquêmica e para a proteção de rins isquêmicos - Google Patents

Antagonistas do receptor at1 para prevenir e tratar a deficiência renal pós-isquêmica e para a proteção de rins isquêmicos

Info

Publication number: BR9611007A
Authority: BR; Brazil
Prior art keywords: ischemic; prevent; pct; receptor antagonists; kidney deficiency
Prior art date: 1995-10-06

Application number

BR9611007A

Other languages

English (en)

Inventor

Ultich Humke

Original Assignee

Novartis Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1995-10-06

Filing date

1996-09-24

Publication date

1999-07-13

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=4242452&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR9611007(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1996-09-24 Application filed by Novartis Ag filed Critical Novartis Ag

1999-07-13 Publication of BR9611007A publication Critical patent/BR9611007A/pt

Links

210000003734 kidney Anatomy 0.000 title abstract 3
230000000302 ischemic effect Effects 0.000 title abstract 2
239000002333 angiotensin II receptor antagonist Substances 0.000 title 1
230000007812 deficiency Effects 0.000 title 1
150000003839 salts Chemical class 0.000 abstract 2
ACWBQPMHZXGDFX-QFIPXVFZSA-N valsartan Chemical compound C1=CC(CN(C(=O)CCCC)[C@@H](C(C)C)C(O)=O)=CC=C1C1=CC=CC=C1C1=NN=NN1 ACWBQPMHZXGDFX-QFIPXVFZSA-N 0.000 abstract 2
239000004072 C09CA03 - Valsartan Substances 0.000 abstract 1
208000001647 Renal Insufficiency Diseases 0.000 abstract 1
230000001154 acute effect Effects 0.000 abstract 1
230000001684 chronic effect Effects 0.000 abstract 1
150000001875 compounds Chemical class 0.000 abstract 1
201000006370 kidney failure Diseases 0.000 abstract 1
229960004699 valsartan Drugs 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Urology & Nephrology (AREA)
Toxicology (AREA)
Vascular Medicine (AREA)
Cardiology (AREA)
Surgery (AREA)
Heart & Thoracic Surgery (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Plural Heterocyclic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)

BR9611007A 1995-10-06 1996-09-24 Antagonistas do receptor at1 para prevenir e tratar a deficiência renal pós-isquêmica e para a proteção de rins isquêmicos BR9611007A (pt)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
CH282595		1995-10-06
PCT/EP1996/004162 WO1997013513A1 (en)	1995-10-06	1996-09-24	At1-receptor antagonists for preventing and treating postischemic renal failure and for protecting ischemic kidneys

Publications (1)

Publication Number	Publication Date
BR9611007A true BR9611007A (pt)	1999-07-13

Family

ID=4242452

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BR9611007A BR9611007A (pt)	1995-10-06	1996-09-24	Antagonistas do receptor at1 para prevenir e tratar a deficiência renal pós-isquêmica e para a proteção de rins isquêmicos

Country Status (16)

Country	Link
US (1)	US6071931A (pt)
EP (1)	EP0853477B1 (pt)
JP (3)	JPH11513395A (pt)
AT (1)	ATE225657T1 (pt)
AU (1)	AU7213296A (pt)
BR (1)	BR9611007A (pt)
CA (1)	CA2232663C (pt)
CY (1)	CY2428B1 (pt)
DE (1)	DE69624253T2 (pt)
DK (1)	DK0853477T3 (pt)
ES (1)	ES2184892T3 (pt)
MY (1)	MY119312A (pt)
PT (1)	PT853477E (pt)
TW (1)	TW445147B (pt)
WO (1)	WO1997013513A1 (pt)
ZA (1)	ZA968378B (pt)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0855392A3 (de)	1997-01-22	2000-01-05	Hoechst Aktiengesellschaft	Fünfgliedrige Heterocyclen mit Biphenylsulfonylsubstitution, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
IT1295405B1 (it)	1997-09-30	1999-05-12	Merck Sharp & Dohme Italia S P	Uso di un antagonista recettoriale di angiotensina ii per la preparazione di farmaci per aumentare il tasso di sopravvivenza di
DE69830069T3 (de) *	1997-10-17	2012-02-09	Ark Therapeutics Ltd.	Verwendung von hemmern des renin-angiotensin systems zur behandlung von hypoxie oder verringertem stoffwechsel
KR100646716B1 (ko)	1998-12-23	2006-11-17	노파르티스 아게	Ａｔ-1 또는 ａｔ-2 수용체의 증가와 관련된 질환의치료에 있어서 ａｔ-1 수용체 길항제 또는 ａｔ-2 수용체조절제의 용도
SE9902597D0 (sv) *	1999-07-06	1999-07-06	Astra Ab	New use
CZ20024180A3 (cs) *	2000-06-22	2003-04-16	Novartis Ag	Pevné orální farmaceutické kompozice obsahující valsartan
BR0112665A (pt) *	2000-07-19	2003-06-24	Novartis Ag	Sais
CA2420055C (en) *	2000-08-25	2010-06-01	Takeda Chemical Industries, Ltd.	Fibrinogen-lowering agent
WO2003089417A1 (en) *	2002-04-15	2003-10-30	Dr. Reddy's Laboratories Limited	Novel crystalline forms of (s)-n-(1-carboxy-2-methyl-prop-1-yl) -n-pentanoyl-n- [2’-(1h-tetrazol-5-yl-)- biphenyl-4-yl methyl] amine (valsartan)
GB0222056D0 (en) *	2002-09-23	2002-10-30	Novartis Ag	Process for the manufacture of organic compounds
WO2005097109A1 (en) *	2004-04-01	2005-10-20	Daniel Batlle	Methods for achieving a protective ace2 expression level
US10716749B2 (en) *	2005-11-03	2020-07-21	Palo Alto Investors	Methods and compositions for treating a renal disease condition in a subject
JP2011063518A (ja) *	2009-09-15	2011-03-31	Tohoku Univ	Ａｒｂ及び／又はグリタゾン系血糖降下物質を含有するｏａｔｐ−ｒ遺伝子発現増強組成物
RU2456615C1 (ru) *	2011-03-25	2012-07-20	Федеральное государственное учреждение "Федеральный научный центр трансплантологии и искусственных органов имени академика В.И. Шумакова" Министерства здравоохранения и социального развития Российской Федерации	Способ профилактики отторжения трансплантата трупной почки
WO2018002673A1 (en)	2016-07-01	2018-01-04	N4 Pharma Uk Limited	Novel formulations of angiotensin ii receptor antagonists

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA1334092C (en) *	1986-07-11	1995-01-24	David John Carini	Angiotensin ii receptor blocking imidazoles
DK0403159T3 (da) *	1989-06-14	2000-08-14	Smithkline Beecham Corp	Imidazolylalkensyrer
IE70593B1 (en) *	1989-09-29	1996-12-11	Eisai Co Ltd	Biphenylmethane derivative the use of it and pharmacological compositions containing same
DE122010000024I1 (de) *	1990-02-19	2010-07-08	Novartis Ag	Acylverbindungen
PT97078B (pt) *	1990-03-20	1997-07-31	Sanofi Sa	Processo para a preparacao de derivados heterociclicos n-substituidos e de composicoes farmaceuticas que os contem
US5196444A (en) *	1990-04-27	1993-03-23	Takeda Chemical Industries, Ltd.	1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]benzimidazole-7-carboxylate and compositions and methods of pharmaceutical use thereof
IE912956A1 (en) *	1990-09-10	1992-03-11	Abbott Lab	Angiotensin ii receptor antagonists
SI9210098B (sl) *	1991-02-06	2000-06-30	Dr. Karl Thomae	Benzimidazoli, zdravila, ki te spojine vsebujejo, in postopek za njihovo pripravo
US5196537A (en) *	1991-03-21	1993-03-23	G. D. Searle & Co.	5-apylheteroarylalkyl-1,3,5-trisubstituted-1,2,4-triazole compounds for treatment of circulatory disorders
GB9110636D0 (en) *	1991-05-16	1991-07-03	Glaxo Group Ltd	Chemical compounds
EP0636027B1 (en) *	1992-04-13	1999-07-07	Zeneca Limited	Angiotensin ii antagonists against disorders associated with impaired neuronal conduction velocity, especially diabetic neuropathy
EP0720477A1 (en) *	1992-09-09	1996-07-10	Vanderbilt University	Method and compositions for maintaining glomerular filtration rate while inhibition extracellular matrix accumulation
EP0629408A1 (en) *	1993-06-16	1994-12-21	LABORATOIRES MERCK, SHARP & DOHME-CHIBRET	Combination of angiotensin converting enzyme inhibitors and AII antagonists

1996
- 1996-09-24 BR BR9611007A patent/BR9611007A/pt not_active Application Discontinuation
- 1996-09-24 CA CA002232663A patent/CA2232663C/en not_active Expired - Fee Related
- 1996-09-24 MY MYPI96003925A patent/MY119312A/en unknown
- 1996-09-24 EP EP96933369A patent/EP0853477B1/en not_active Expired - Lifetime
- 1996-09-24 US US09/051,345 patent/US6071931A/en not_active Expired - Lifetime
- 1996-09-24 DK DK96933369T patent/DK0853477T3/da active
- 1996-09-24 WO PCT/EP1996/004162 patent/WO1997013513A1/en not_active Ceased
- 1996-09-24 AT AT96933369T patent/ATE225657T1/de active
- 1996-09-24 PT PT96933369T patent/PT853477E/pt unknown
- 1996-09-24 AU AU72132/96A patent/AU7213296A/en not_active Abandoned
- 1996-09-24 DE DE69624253T patent/DE69624253T2/de not_active Expired - Lifetime
- 1996-09-24 JP JP9514668A patent/JPH11513395A/ja not_active Withdrawn
- 1996-09-24 ES ES96933369T patent/ES2184892T3/es not_active Expired - Lifetime
- 1996-09-25 TW TW085111691A patent/TW445147B/zh not_active IP Right Cessation
- 1996-10-04 ZA ZA968378A patent/ZA968378B/xx unknown
2004
- 2004-02-27 CY CY0400015A patent/CY2428B1/xx unknown
2007
- 2007-10-02 JP JP2007258682A patent/JP2008019273A/ja not_active Ceased
2011
- 2011-08-12 JP JP2011176948A patent/JP2011256195A/ja active Pending

Also Published As

Publication number	Publication date
EP0853477B1 (en)	2002-10-09
CA2232663C (en)	2008-04-08
CY2428B1 (en)	2004-11-12
MY119312A (en)	2005-05-31
ATE225657T1 (de)	2002-10-15
DE69624253D1 (de)	2002-11-14
EP0853477A1 (en)	1998-07-22
ZA968378B (en)	1997-04-07
TW445147B (en)	2001-07-11
US6071931A (en)	2000-06-06
WO1997013513A1 (en)	1997-04-17
JP2008019273A (ja)	2008-01-31
DK0853477T3 (da)	2003-02-10
JP2011256195A (ja)	2011-12-22
CA2232663A1 (en)	1997-04-17
PT853477E (pt)	2003-01-31
JPH11513395A (ja)	1999-11-16
DE69624253T2 (de)	2003-08-07
ES2184892T3 (es)	2003-04-16
AU7213296A (en)	1997-04-30

Legal Events

Date	Code	Title	Description
2002-06-04	EG	Technical examination (opinion): publication of technical examination (opinion)
2005-10-25	B09B	Patent application refused [chapter 9.2 patent gazette]	Free format text: INDEFERIMENTO DO PRESENTE PEDIDO, COM BASE NO DISPOSTO NO ART. 229-A DA LEI 10.196 DE 14 DE FEVEREIRO DE 2001 E DADO COMO CONCLUIDO O EXAME.

Publication	Publication Date	Title
DK0853477T3 (da)	2003-02-10	AT1-receptor-antagonister til forebyggelse og behandling af postiskæmisk nyresvigt og til beskyttelse af iskæmiske nyrer
DK0743852T3 (da)	2005-10-17	Behandling af glaukom med normalt tryk med valsartan
LU93229I2 (fr)	2016-11-21	"pitolisant et ses sels pharmaceutiquement acceptables, tel que chlorhydrate"
TNSN01122A1 (fr)	2005-11-10	Composes heterocycliques comme coordonnats du recepteur gabaa
WO2001072714A3 (en)	2002-05-30	Aryl substituted pyrazoles, triazoles and tetrazoles as sodium channel blocker
EP0805149A4 (en)	1998-03-11	NEW 2,3-DIKETOPIPERAZINE DERIVATIVE OR ITS SALT
SG11201901747VA (en)	2019-03-28	Inhibitors of cellular metabolic processes
ATE196295T1 (de)	2000-09-15	Corticotropinfreisetzungsfaktor antagonisten
TR200102839T2 (tr)	2002-04-22	LH agonistleri olarak faydalı bisiklik heteroaromatik bileşikler.
NO971470D0 (no)	1997-04-01	Nye pyrimidon-derivater med fungicid aktivitet
BR0112665A (pt)	2003-06-24	Sais
DE69413019D1 (de)	1998-10-08	Stickstoff enthaltende kondensierte heterocylen
ES2105286T3 (es)	1997-10-16	Derivados de etanolamina que tienen actividades simpatomimetica y anti-polaquiuria.
DE69714220D1 (de)	2002-08-29	Campotecinderivate und ihre verwendung als antitumormittel
ATE182891T1 (de)	1999-08-15	Indazolderivate
BRPI0412159A (pt)	2006-08-22	emprego
SE9902267D0 (sv)	1999-06-16	New compounds
BR9912684A (pt)	2001-05-02	Composto de fórmula (i), composição farmacêutica compreendendo o composto, método, processo e seu uso
SG52662A1 (en)	1998-09-28	Arylkalkyl-amines and -amides having anticonvulsant and neuroprotective properties
NZ507303A (en)	2002-09-27	Quinolin-4-yl derivatives II and their use in treating neurodegenerative disease
BR0007686A (pt)	2001-11-06	Uso de antagonistas receptores da angiotensina ii para tratar enfartação miocárdia aguda
WO2002014532A3 (en)	2002-06-13	Method for identifying modulators of 'mec'-induced functions of ccr3 and/or ccr10
BRPI0507802A (pt)	2007-07-10	composto, composição, e, método para tratar inflamação ou um distúrbio metabólico
WO2008060807A3 (en)	2008-07-31	Method of providing bearer certificates for private civil security benefits
AU4625299A (en)	2000-02-01	Use of a pharmaceutical composition containing, in combination, an antagonist of the angiotensin ii AT1, receptors and indomethacin for making a medicine treating chronic glomerulonephritis